^
    Back
    Association details:
    Biomarker:HDAC11 underexpression
    Cancer:Multiple Myeloma
    Drug:elevenostat (JB3-22) (HDAC11 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    ASH 2018
    Title:

    Functional Analysis of HDAC11 in Plasma Cell Development and Multiple Myeloma Survival

    Published date:
    11/01/2018
    Excerpt:
    The HDAC11-selective inhibitor elevenostat showed significant cytotoxic potential in different MM cell lines that express moderate to high level of HDAC11, with IC50 values ranging 0.6-2.0 µM. Consistently, MM cell lines expressing null/very low level of HDAC11 were insensitive to elevenostat.
    DOI:
    https://doi.org/10.1182/blood-2018-99-119119